New thoughts about renaming nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2020.06.001
- VernacularTitle:非酒精性脂肪性肝病更名带来的新思考
- Author:
Xin GAO
1
Author Information
1. Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Publication Type:Research Article
- Keywords:
non-alcoholic fatty liver disease;
metabolic associated fatty liver disease;
terminology as topic
- From:
Journal of Clinical Hepatology
2020;36(6):1201-1204
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease involving metabolic disorder and is more common in patients with obesity and type 2 diabetes mellitus (T2DM), with similar adverse outcomes to these two comorbidities. For a long time, NAFLD has emphasized liver lesions and outcomes of liver diseases, and when treating T2DM according to the current clinical guidelines for diabetes, endocrinologists often neglect the screening, diagnosis, and treatment of liver lesions. Therefore, in clinical practice, NAFLD renamed as metabolic-associated fatty liver disease has important practical significance. Strategies for T2DM prevention and treatment aiming at reducing liver lipid content require multidisciplinary cooperation, and prevention and treatment of obesity, fatty liver disease, and diabetes with the same concepts can help to implement the prevention and treatment of the most common chronic diseases.
